APA citiranje

Brahmer, J., Balmanoukian, A., Goldberg, S., Ou, S., Blake-Haskins, A., Karakunnel, J., . . . Antonia, S. (2014). Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer.

Citação norma Chicago

Brahmer, Julie, Ani Balmanoukian, Sarah Goldberg, Sai-Hong Ou, Andrew Blake-Haskins, Joyson Karakunnel, Paul Stockman, Naiyer Rizvi, and Scott Antonia. "Development of MEDI4736, an Anti-programmed Cell Death Ligand 1 (PD-L1) Antibody, As Monotherapy or in Combination With Other Therapies in the Treatment of Non-small Cell Lung Cancer (NSCLC)." J Immunother Cancer 2014.

MLA citiranje

Brahmer, Julie, et al. "Development of MEDI4736, an Anti-programmed Cell Death Ligand 1 (PD-L1) Antibody, As Monotherapy or in Combination With Other Therapies in the Treatment of Non-small Cell Lung Cancer (NSCLC)." J Immunother Cancer 2014.